Journal
PLOS ONE
Volume 11, Issue 3, Pages -Publisher
PUBLIC LIBRARY SCIENCE
DOI: 10.1371/journal.pone.0151345
Keywords
-
Categories
Funding
- National Natural Science Foundation of China [81230068, 81373091, 81302502, 81302490, 81473049]
- Natural Science Foundation of Jiangsu Province [BK2012842, BK20130641]
- Key Program for Basic Research of Jiangsu Provincial Department of Education [12KJA330002]
- Specialized Research Fund for the Doctoral Program of Higher education of China [20130092120063]
- Jiangsu Provincial Training Programs of Innovation and Entrepreneurship for Undergraduates [201412682004Y]
- Jiangsu Provincial Science and Technology Innovation Team
- Priority Academic Program Development of Jiangsu Higher Education Institutions (Public Health and Preventive Medicine)
Ask authors/readers for more resources
Background In the past decades, a good deal of studies has provided the possibility of the circulating microRNAs (miRNAs) as noninvasive biomarkers for cancer diagnosis. The aim of our study was to detect the levels of circulating miRNAs in tissues and plasmas of gastric cancer (GC) patients and evaluate their diagnostic value. Methods Tissue samples were collected from 85 GC patients. Plasma samples were collected from 285 GC patients and 285 matched controls. Differentially expressed miRNAs were filtered with by Agilent Human miRNA Microarray and TaqMan low density array (TLDA) with pooled samples, followed by the quantitative reverse transcription polymerase chain reaction (qRT-PCR) validation. Receiver operating characteristic (ROC) curves were structured to evaluate the diagnostic accuracy of the miRNAs. The plasma level of miR-26a in GC patients of different clinical stages was compared. Results Four miRNAs (miR-26a, miR-142-3p, miR-148a, and miR-195) revealed coincidentally decreased levels in tissue and plasma of the GC patients compared with controls, and ROC curves were constructed to demonstrate that miR-26a had a highest area under the ROC curve (AUC) of 0.882. Furthermore, miR-26a was stably detected in the plasma of GC patients with different clinical characteristics. Conclusion Plasma miR-26a may provide a novel and stable marker of gastric cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available